Blood and Blood Components Market Size & Share 2026-2035

Blood and Blood Components Market Size

The blood and blood components market was valued at USD 14.2 billion in 2025. It is projected to reach USD 14.6 billion in 2026 and USD 20.7 billion by 2035, reflecting an approximately 4% CAGR from 2026 to 2035.

Demand rests on an essential clinical service rather than discretionary consumption. Blood supports emergency hemorrhage control, surgery, cancer treatment, obstetric care, and chronic hematological disease management, while component separation allows a single donation to serve several patients. WHO reports that approximately 120.4 million blood donations are collected annually worldwide; high-income countries collect 36% of donations despite representing 15% of the global population ^{[1]World Health Organization, Blood safety and availability, 2024, who.int}. The supply base has strengthened through voluntary donation: WHO reported that voluntary, unpaid donors accounted for more than 85% of the roughly 120 million donations collected in 2023 ^{[2]World Health Organization, Safe blood supply improves as voluntary donations exceed 85%, June 2026, who.int}.

The market is increasingly organized around component therapy. In high-income systems, 98% of collected blood is separated into components, supporting the 2025 value split of USD 8,849.8 million for blood components, or 62.5% of the market, versus USD 5,309.9 million for whole blood. Red blood cells account for USD 5,787.8 million, or 65.4% of component value; platelets account for USD 1,637.2 million, plasma for USD 1,079.7 million, and white blood cells for USD 345.1 million.

Trauma and surgery is the largest application, valued at USD 6,386.0 million in 2025 and representing 45.1% of market value. Blood disorders contribute USD 4,601.9 million and are expected to grow fastest at approximately 4.3% CAGR, while cancer treatment represents USD 2,124.0 million. Hospitals account for USD 10,195.0 million, or 72.0% of end-use demand, because they concentrate emergency, surgical, oncology, and complex transfusion services.

Component therapy should continue to take value share because it improves clinical targeting and extracts more therapeutic use from each donation. That shift does not eliminate the strategic relevance of whole blood. Whole blood remains important for trauma resuscitation, military medicine, obstetric emergencies, and settings where fractionation infrastructure is constrained. Providers therefore face two parallel priorities: expanding component capacity where clinical systems can support it, while preserving dependable whole-blood pathways for emergency and lower-resource care.

Key Drivers

Increasing volume of surgeries globally

Surgery creates the largest recurring call on transfusion services. An estimated 313 million surgical procedures are performed globally each year ^{[3]Strauss O et al., Strategies to prevent blood loss and reduce transfusion in surgery, 2024, pmc.ncbi.nlm.nih.gov}. Cardiovascular, orthopedic, transplant, oncology, and trauma procedures require differing combinations of red blood cells, plasma, and platelets, especially when hemorrhage activates massive transfusion protocols. In the United States, approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma are needed daily.

Patient blood-management programs can reduce transfusion intensity per procedure through preoperative anemia management, restrictive thresholds, and intraoperative conservation. However, these efficiency gains do not necessarily offset higher absolute procedure volumes. The commercial implication is that hospitals and blood centers need demand planning tied to procedure mix, not just aggregate admissions. Orthopedic and cardiac cases may raise red-cell needs, while oncology surgery and trauma can create more acute platelet and plasma requirements.

Rising number of people suffering from chronic conditions including cancer

Chronic hematological conditions create repeat demand that is less sensitive to short-term economic cycles than elective care. WHO estimates that anaemia affects 40% of children aged 6–59 months, 37% of pregnant women, and 30% of women aged 15–49 years globally. These figures do not imply that every patient requires transfusion, but they indicate the scale of conditions that can lead to red-cell use when disease is severe, when surgery intervenes, or when maternal and pediatric care is limited.

Cancer care adds a second source of repeat demand. Global leukemia incidence reached 487,294 new cases in 2022. Chemotherapy, stem-cell transplantation, marrow suppression, and bleeding complications can require recurring red-cell and platelet support. The United States also has approximately 100,000 people living with sickle cell disease. New curative therapies may eventually reduce chronic transfusion dependence for some patients, but treatment preparation can temporarily intensify component use. The American Red Cross notes that conditioning for some sickle cell gene-therapy patients may require up to 50 units of blood and 25 units of platelets.

Diagnostic expansion is particularly consequential for bleeding disorders. The World Federation of Hemophilia identified 271,918 people with hemophilia and 110,184 people with von Willebrand disease globally in its 2024 survey. Identification rates remain uneven, with an estimated 8% of the expected hemophilia population identified in Africa and 19% in South East Asia. As diagnosis, factor access, and specialist care improve, demand may shift toward a more formalized treatment pathway that includes component support in resource-constrained settings.

Growing popularity of plasma therapy for sport injuries, cosmetic, and orthopedic procedures

Platelet-rich plasma procedures use autologous blood rather than community donor inventory. Their direct contribution to allogeneic blood demand is therefore limited. Their relevance lies in the broader expansion of blood-handling, separation, and processing infrastructure across orthopedic, sports-medicine, dermatology, and cosmetic settings.

This distinction is important for market interpretation. Rising platelet-rich plasma procedure volumes should not be treated as equivalent to platelet-concentrate demand at blood centers. Instead, they reinforce demand for processing equipment, trained personnel, and clinical familiarity with blood-derived therapies. The strongest effect is likely to occur in technologically mature outpatient markets in North America, Europe, and Asia Pacific.

Several blood donation campaigns undertaken by blood organizations

Voluntary donation campaigns improve supply continuity and safety when they convert occasional donors into repeat donors. WHO's 2024 World Blood Donor Day campaign marked 20 years of international mobilization around voluntary donation. More broadly, voluntary unpaid donations increased by 11.6 million units between 2013 and 2023 across 132 countries.

India illustrates how collection expansion can alter domestic availability. WHO India reported that national blood collection reached 14.6 million units in 2024, up from 12.6 million units in 2023. In Latin America and the Caribbean, donor conversion remains a material opportunity: PAHO reported that voluntary unpaid donors represented 48% of donations across 34 reporting countries. Collection campaigns matter most when they are tied to repeat-donor retention, quality-assured screening, and the ability to process donations into clinically appropriate components.

Key Restraints

Short shelf life of blood components

Perishability is a structural constraint rather than a temporary logistics issue. Red-cell products stored at 2–6°C can be held for up to 42 days, while plasma can be frozen for longer periods; platelet products require storage at 20–24°C with agitation and generally have a five-to-seven-day shelf life ^{[4]Australian Red Cross Lifeblood, Storage and handling of blood products, lifeblood.com.au}. The platelet constraint reflects both functional preservation and bacterial-risk management, leaving blood centers and hospitals with little opportunity to build durable inventory.

A short shelf life changes the economics of the market. It raises the importance of collection frequency, demand forecasting, inventory rotation, and inter-regional redistribution. It also increases exposure to localized weather disruptions, transport failures, staffing constraints, and cyber incidents. Cold-stored platelet approaches may extend effective storage to as long as 21 days in selected settings, but their broader adoption requires clinical protocols and standardized operating practices.

Pathogen-reduction technologies can offer a narrower but meaningful mitigation pathway. These technologies can reduce bacterial contamination risk and support seven-day platelet storage in closed systems. Their value proposition is therefore operational as well as clinical: they can reduce wastage risk in a product category where a single missed collection cycle may affect hospital availability.

Transfusion transmitted infection related to donated blood

Blood screening has materially reduced transfusion-transmitted infection risk, but the required safety architecture remains costly and unevenly available. WHO recommends that each donation be screened for HIV, hepatitis B, hepatitis C, and syphilis. Ten countries were unable to screen every donation for one or more of these infections, and only 63% of blood-screening laboratories participated in external quality-assessment programs.

Layered screening produces very low residual risk in mature systems. Canada Blood Services reported residual risks of one in 13.2 million donations for HIV, one in 72.1 million for hepatitis C, and one in 4.1 million for hepatitis B. In the United Kingdom, assessment of 136 possible transfusion-transmitted infection reports in 2024 identified no confirmed transmissions across UK blood services. Yet bacterial contamination remains a particular platelet concern. The European Commission recorded 41 transfusion-transmitted infection cases across EU member states in 2023, including 30 bacterial cases and five fatalities, four associated with platelet transfusions.

The operational burden is greatest where testing infrastructure, quality systems, and voluntary donation participation are incomplete. Infection risk can suppress donor confidence, increase deferrals, complicate cross-border plasma trade, and require investment in nucleic-acid testing, quality assurance, and pathogen reduction. These measures strengthen safety but also increase the fixed cost of building a reliable blood system.

The most resilient blood-service models will combine safety investment with network flexibility. A mature system can redistribute products, maintain validated testing, and recover from localized disruption. Systems still building voluntary donation and quality-assurance capacity have greater latent growth potential, but their market development will be limited unless collection growth is accompanied by processing, screening, and cold-chain capability.

Blood and Blood Components Market Segment Analysis

By Product

Whole blood accounts for USD 5,309.9 million, or 37.5% of 2025 market value. Its role is concentrated in emergency resuscitation, military trauma, obstetric hemorrhage, and lower-resource settings where component separation is unavailable or impractical. WHO reports that component separation is substantially less prevalent in lower-income countries, where only 52% of collected blood may be separated into components. Whole blood therefore remains clinically and commercially relevant where rapid treatment and limited infrastructure outweigh the advantages of component-specific therapy.

Blood components represent USD 8,849.8 million and underpin the market's clinical specialization. Red blood cells are the largest category at USD 5,787.8 million. Their demand base spans surgical blood loss, severe anemia, cancer treatment, hemoglobinopathies, and trauma. Platelets, valued at USD 1,637.2 million, are smaller in value but disproportionately demanding to manage because of their storage limitations and importance in chemotherapy-induced thrombocytopenia and transplant care.

Plasma represents USD 1,079.7 million in 2025 and serves coagulation management, massive hemorrhage protocols, and liver-related indications. It also connects the transfusion system to the fractionation economy. WHO reported that 21.5 million liters of plasma were fractionated across 36 reporting countries in 2023. Canada Blood Services has expanded its source-plasma network to 11 sites to support greater domestic immunoglobulin self-sufficiency ^{[5]Canadian Blood Services, 2024 year in review, blood.ca}. White blood cells represent USD 345.1 million and remain highly specialized because granulocyte transfusions require rapid use, careful donor selection, and specific clinical indications.

By Application

Trauma and surgery leads the application mix at USD 6,386.0 million and 45.1% share. Its approximately 4.0% CAGR reflects the breadth of surgical demand rather than reliance on a single procedure category. The segment benefits from expanding procedural capacity but is moderated by patient blood-management practices that reduce avoidable transfusion.

Blood disorders are valued at USD 4,601.9 million and represent the fastest-growing application at approximately 4.3% CAGR. Anaemia accounts for USD 3,235.1 million, or 70.3% of this segment, while bleeding disorders account for USD 1,132.1 million. Hemophilia represents USD 991.7 million, or 87.6% of bleeding-disorder value, and von Willebrand disease represents USD 140.4 million. The growth opportunity is most pronounced where diagnosis and treatment access are expanding from a low base, particularly in regions with a large gap between expected and identified hemophilia populations ^{[6]World Federation of Hemophilia, Report on the Annual Global Survey 2024, wfh.org}.

Cancer treatment contributes USD 2,124.0 million and grows at approximately 3.6% CAGR. Its blood-product demand arises from marrow suppression and bleeding risk during chemotherapy, radiation, and transplantation. Other applications account for USD 1,047.8 million and include obstetric hemorrhage, neonatal transfusion, organ transplantation, and therapeutic apheresis. WHO identifies obstetric complications as an important use of blood transfusion, particularly where access to timely emergency care is limited.

By End Use

Hospitals account for USD 10,195.0 million, or 72.0% of 2025 value, and are forecast to grow at approximately 4.1% CAGR. They remain the primary setting for emergency transfusion, oncology, complex surgery, and intensive care. The American Red Cross supplies approximately 6.5 million blood products annually to around 2,600 hospitals and transfusion centers in the United States. Hospital demand is increasingly shaped by electronic inventory tools, cross-matching practice, transfusion thresholds, and formal ordering protocols.

Ambulatory surgical centres account for USD 2,860.3 million and grow at approximately 3.8% CAGR. Their expansion reflects the migration of selected elective procedures from inpatient settings, although their blood use per case is generally lower than that of hospitals managing trauma, major oncology, and complex cardiovascular surgery. Other end users represent USD 1,104.5 million and include specialty clinics, dialysis services, standalone blood banks, and chronic-care settings.

The fastest long-term demand expansion may occur where disorder diagnosis becomes more complete rather than where existing utilization simply rises. Hemophilia identification gaps in Africa and South East Asia indicate that future demand can emerge through access and diagnosis improvements. That opportunity will require more than collection growth: it depends on laboratories, specialist referral systems, component availability, and the financing needed to convert identified patients into sustained treatment demand.

Blood and Blood Components Market Regional Analysis

North America

North America is the largest regional market, valued at USD 5,638.4 million in 2025 and representing approximately 39.8% of global value. The United States accounts for approximately USD 5.0 billion, compared with USD 4.6 billion in 2022 and USD 4.7 billion in 2023. Its mature collection network supports high clinical utilization but is vulnerable to donor attrition and disruption. America's Blood Centers reported that the American Red Cross engages approximately 3.5 million donors through about 150,000 annual blood drives. The American Red Cross declared an emergency blood shortage in January 2024, citing donor participation at its lowest level in 20 years.

Canada represents approximately USD 609 million in 2025. Its operating focus includes safety and plasma self-sufficiency. The Canadian Blood Services plasma-network expansion illustrates a regional effort to reduce exposure to imported immunoglobulin supply while retaining strict surveillance and screening standards ^{[7]AABB, Canadian Blood Services Releases 2024 Surveillance Report, November 2025, aabb.org}.

Europe

Europe accounts for USD 3,903.4 million in 2025, or approximately 27.6% of the global market. Demand is supported by established hospital infrastructure, aging populations, and a large burden of cancer and chronic disease. NHS Blood and Transplant collected approximately 1.8 million donations from 964,000 donors in 2024. Its donor-diversification challenge is commercially relevant: 48% of Ro blood-type demand in 2024–25 was unfilled by available Ro-type supply, demonstrating that aggregate donation volume does not ensure availability of clinically appropriate units for all recipient groups.

France's blood system illustrates the safety performance available in mature national services. Santé publique France reported more than 2.6 million donations from 1.5 million donors in 2024, with estimated residual risks of one in 8.9 million donations for HIV, one in 2.6 million for hepatitis B, and one in 126.3 million for hepatitis C ^{[8]Santé publique France, Don de sang: données 2024, santepubliquefrance.fr}. European blood services are also advancing pathogen-reduction approaches, particularly for platelet products, as a response to bacterial risk and contingency-planning requirements.

Asia Pacific

Asia Pacific represents USD 3,260.6 million in 2025 and is the fastest-growing region at approximately 4.4% CAGR. The region combines growing surgical capacity, major chronic-disease burdens, and uneven blood-system maturity. India's 2024 collection increase to 14.6 million units demonstrates the impact of national mobilization, but collection expansion must be matched by component preparation, screening, and distribution capacity to improve clinical access.

China's blood-products industry is also increasing its regulatory and manufacturing focus. The opportunity is particularly relevant to plasma collection and fractionation, where greater domestic capacity could reduce import dependence for albumin and immunoglobulin. Japan faces a different balance: population aging increases demand for transfusion services while narrowing the potential donor base. A national survey found that the red-cell discard rate declined from 1.4% to 0.7% in 2023 after an extension of the product-usage period. This illustrates how policy and inventory management can release effective supply without increasing donations.

Latin America

Latin America accounts for USD 989.8 million in 2025. Brazil is the largest regional market, while voluntary-donor conversion remains an important supply-development issue across the region. PAHO's finding that voluntary unpaid donors represented 48% of donations in 34 reporting countries points to the importance of building repeat-donor programs and reducing reliance on replacement donation. Greater voluntary participation can improve both collection reliability and the safety profile of supply.

Middle East & Africa

Middle East & Africa is valued at USD 367.4 million in 2025. The lower market value reflects supply-system constraints rather than a lack of clinical need. WHO's Regional Office for Africa reported average collection of approximately 5.2 units per 1,000 population across the region, below the WHO benchmark of 10 units per 1,000 population. Saudi Arabia, South Africa, and the UAE represent relatively more developed markets, but broader growth will depend on voluntary collection, testing coverage, component-processing capacity, and dependable transport infrastructure.

Asia Pacific's higher forecast growth reflects a different market position: collection systems, surgical access, and plasma infrastructure are still expanding. India's collection growth and China's emphasis on blood-product oversight support this trajectory, while Japan shows that mature Asian systems can extract more availability from existing inventory. Middle East & Africa has the largest gap between latent demand and formal supply capacity; its long-term opportunity depends on whether health-system investment converts low collection rates into safe, component-ready inventory.

Blood and Blood Components Market Share & Competitive Landscape

Competition is organized around collection coverage, donor loyalty, testing quality, processing capability, hospital relationships, and emergency redistribution capacity. National blood services and nonprofit regional blood centers remain central because blood supply is locally collected, regulated, and time-sensitive. Scale can improve redistribution and technology investment, but regional trust and donor recruitment remain decisive because collection cannot be fully centralized.

The authorized competitive set comprises American Red Cross, America's Blood Centers, AVIS, Bloodworks Northwest, Canada Blood Services, Carter BloodCare, ImpactLife, Indian Red Cross Society, NHS Blood and Transplant, Northern Ireland Blood Transfusion Service, OneBlood, Scottish National Blood Transfusion Service, Versiti, Vitalant, and Welsh Blood Service.

American Red Cross remains a major U.S. supplier, providing approximately 6.5 million blood products annually to around 2,600 hospitals and transfusion centers. America's Blood Centers represents community-based blood centers that collectively supply approximately 60% of U.S. blood needs and serve more than 3,500 healthcare facilities. Their combined role demonstrates that the U.S. system depends on both national scale and regional collection infrastructure.

Canada Blood Services is expanding source-plasma collection as a strategic response to immunoglobulin dependency. NHS Blood and Transplant is focused on donor diversification to improve access to Ro blood types used by many sickle cell patients. These initiatives show that competitive capability is increasingly defined by product-specific availability and donor composition, not only by total collections.

Technology adoption is becoming a differentiator for regional operators. Carter BloodCare completed a transition to Terumo's Reveos automated whole-blood processing system and Lumia software platform in 2025. Such automation can improve component consistency, traceability, and operating efficiency, although it requires capital investment and workforce adaptation. OneBlood's FDA-licensed high-titer COVID-19 convalescent plasma program illustrates how blood centers can participate in specialized biologic pathways alongside conventional transfusion supply.

AVIS

AVIS is Italy's national voluntary blood donor association, operating through a federated network of provincial and local associations. It serves as a primary institutional channel for voluntary, unpaid donation in Italy and coordinates with the National Blood Centre and regional health authorities. Its role extends beyond collection mobilization: AVIS supports the donor culture that underpins Italy's blood system and provides technical cooperation for voluntary-donation program development internationally.

Bloodworks Northwest

Bloodworks Northwest is a primary supplier to approximately 95 hospitals and health systems in Washington, Oregon, and Alaska. Its Bloodworks Research Institute links collection and supply operations with research in transfusion medicine, hematology, and blood banking. The organization also contributes plasma to immunoglobulin manufacturing supply chains and participates in AABB-coordinated national blood-exchange programs, providing a mechanism to address regional imbalances during shortages.

ImpactLife

ImpactLife, formerly Mississippi Valley Regional Blood Center, serves approximately 120 hospitals across Illinois, Iowa, Missouri, and Wisconsin through fixed and mobile collection sites. It participates in AABB's National Blood Exchange and emphasizes community donor recruitment, including programs directed at first-time and younger donors. These activities are important in a market where recurring donor participation directly affects the resilience of local hospital supply.

Indian Red Cross Society

The Indian Red Cross Society operates blood banks and blood-component laboratories across India. It coordinates blood-donation camps and hospital partnerships with the National Blood Transfusion Council and State Blood Transfusion Councils. India's collection reached 14.6 million units in 2024, a 15% increase over 2023. The organization's contribution to mobilization and its alignment with screening and component-preparation standards position it as a relevant participant in the development of India's blood-safety infrastructure.

Northern Ireland Blood Transfusion Service

Northern Ireland Blood Transfusion Service is the blood-transfusion authority for Northern Ireland and operates within the UK safety-surveillance framework coordinated through NHS Blood and Transplant and the UK Health Security Agency. The UK investigation of 136 possible transfusion-transmitted infection reports in 2024 found no confirmed transmissions across UK blood services. NIBTS supports transfusion-medicine training and haemovigilance and participates in the SHOT reporting framework.

Scottish National Blood Transfusion Service

Scottish National Blood Transfusion Service, operating through NHS National Services Scotland, is responsible for collection, component preparation, and supply to Scottish hospitals. The service has implemented universal leukodepletion of blood products to reduce the risk of transfusion-associated graft-versus-host disease. It coordinates with NHS Blood and Transplant on donor-base strategy and supply-chain resilience and also manages stem-cell and cord-blood programs for patients requiring hematopoietic transplantation.

Versiti

Versiti is a Milwaukee-based not-for-profit blood center and biotherapeutics organization supplying blood products and transfusion-medicine services to approximately 160 hospitals and health systems across Indiana, Illinois, Michigan, Ohio, and Wisconsin. Its Versiti Blood Research Institute conducts clinical and translational work in hematology, coagulation, and transfusion medicine. Participation in the national blood-exchange system allows the organization to support continuity of regional supply during shortage events.

Vitalant

Vitalant is the largest independent not-for-profit blood-services organization in the United States focused exclusively on blood and comprehensive transfusion-medicine services. It operates approximately 115 donation centers and hosts approximately 60,000 blood drives annually, providing blood and specialized services to around 900 hospitals across more than two dozen states ^{[9]Vitalant, Purpose and Network, vitalant.org}. The organization was formed through the strategic merger of regional blood centers beginning in 2015 and consolidated under the Vitalant brand in 2018. Its service portfolio also includes clinical apheresis, laboratory services, and transfusion-medicine support for hospital partners.

Welsh Blood Service

Welsh Blood Service is the statutory organization responsible for collecting, processing, and supplying blood and blood components to hospitals in Wales under Velindre University NHS Trust. It coordinates with NHS Blood and Transplant, Northern Ireland Blood Transfusion Service, and Scottish National Blood Transfusion Service on safety standards and haemovigilance. Its targeted donor-recruitment work includes outreach to minority ethnic communities to improve the availability of appropriately matched donations. The service also contributes to the UK SHOT haemovigilance framework.

Recent Industry Developments

• January 2025: OneBlood announced FDA licensure for high-titer COVID-19 convalescent plasma, following approval in December 2024. The product is intended for immunocompromised COVID-19 patients and represented the first licensed CCP program held by a U.S. blood center.

• January–February 2025: A cybersecurity incident at New York Blood Center Enterprises slowed blood-processing operations. AABB's Interorganizational Disaster Task Force coordinated emergency redistribution to protect supply continuity.

• 2025: Carter BloodCare completed its transition to Terumo Blood and Cell Technologies' Reveos automated whole-blood processing system and Lumia software platform.

• July–August 2024: A ransomware attack disrupted OneBlood information systems and affected a blood center serving more than 250 hospitals in the southeastern United States.

• August 2024: The American Red Cross reported critical blood-supply conditions after a substantial summer inventory decline, intensifying donor-recruitment activity.